D Molecular Therapeutics (NASDAQ:FDMT) executives said the company is seeing strong clinical trial momentum for its lead retinal gene therapy candidate, 4D-150, as it advances through late-stage devel ...
This clinical-stage biotech develops innovative retinal disease therapies, with its lead candidate advancing through ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results